PM
PTLA

Penbrook Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Penbrook Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,300
Closed -$209K – 108
2017
Q4 		$209K Buy
+4,300
New +$217K 0.19% 96

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Penbrook Management's PTLA Position: Q1 2018 in Review

Penbrook Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2018, closing a stake of 4,300 shares — an estimated $209K sold.

Penbrook Management first reported a position in PTLA in Q4 2017 and held it in 1 quarter. The position peaked at $209K in Q4 2017. 180 funds tracked by Wall St. Rank hold PTLA as of Q1 2018.

  • Penbrook Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Penbrook Management sold 4,300 Portola Pharmaceuticals, Inc. shares in Q1 2018, an estimated $209K.
  • Penbrook Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Penbrook Management's Portola Pharmaceuticals, Inc. position peaked at $209K in Q4 2017.
  • 180 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2018.

Based on Penbrook Management's 13F filing for Q1 2018, filed 27 Apr 2018.